VivoSim Labs, Inc. (VIVS)
| Market Cap | 2.89M -63.4% |
| Revenue (ttm) | 112,000 -21.1% |
| Net Income | -12.34M |
| EPS | -3.77 |
| Shares Out | 16.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 182,245 |
| Open | 0.1793 |
| Previous Close | 0.1740 |
| Day's Range | 0.1720 - 0.1793 |
| 52-Week Range | 0.1680 - 3.4000 |
| Beta | 1.49 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About VIVS
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies ... [Read more]
Financial Performance
In fiscal year 2026, VivoSim Labs's revenue was $131,000, a decrease of -9.03% compared to the previous year's $144,000. Losses were -$13.84 million, 456.4% more than in 2025.
Financial StatementsNews
VivoSim celebrates updated FDA regulations in non-animal testing methods
VivoSim (VIVS) celebrated the FDA direct final rule updating its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products…
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs As the FDA opens the door to non-animal safety testing, VivoSim's human-rel...
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities New data ...
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans New cross-species capability is designed to help pharma distingu...
VivoSim regains compliance with Nasdaq
VivoSim (VIVS) announced that it received notice from Nasdaq indicating that the company has regained compliance with Nasdaq Listing Rule 5550 which requires registrants to maintain a minimum stockhol...
VivoSim Provides Financial and Listing Compliance Update
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for...
VivoSim files to sell 9.41M shares of common stock for holders
16:18 EDT VivoSim (VIVS) files to sell 9.41M shares of common stock for holders
VivoSim enters China with first commercial sales of NAMkind testing services
VivoSim (VIVS) announced its first commercial sales in China, opening a new market for its NAMkind testing services. VivoSim delivers both toxicology and efficacy testing built on its 3D human…
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-largest pharmaceutical market Initial customer wins bring VivoSim's human-relevant liver and GI testing ...
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for...
Why Is Penny Stock VivoSim Labs (VIVS) Up Today?
VivoSim Labs stock was on the rise Wednesday after it received a new milestone payment from Eli Lilly.
VivoSim receives $5M milestone payment from Eli Lilly
VivoSim (VIVS) announced that it has received a $5M payment from Eli Lilly (LLY). In association with its former inflammatory bowel disease drug program developed previously and sold outright to…
VivoSim sees FY27 revenue up over 500%
The company said, “VivoSim (VIVS) further announced that it anticipates significant revenue growth in Fiscal Year 2027 given its progress in marketing contract research services using NAMs models to p...
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for...
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) VivoSim Demonstrates Leadership in Fi...
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results
VivoSim Announces Pricing of up to a $4 Million Public Offering
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, t...
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity ADCs are a major new market; Company demons...
VivoSim appoints Arumugham Raghunathan as VP, global sales
VivoSim (VIVS) Labs announced the appointment of Dr. Arumugham Raghunathan, PhD as Vice President of Global Sales. Based in the Greater Boston area, Dr. Raghunathan will lead commercial expansion and…
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach wit...
VivoSim to debut antibody drug conjugate data at SOT meeting
VivoSim (VIVS) Labs announced it will attend the Society of Toxicology, SOT, meeting in San Diego, CA that takes place March 22-25 and present new data on its NAMkind liver…
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects Company produces thorough reference testi...
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety...
VivoSim appoints Sethi as Chief Scientific Officer
VivoSim (VIVS) Labs announces it has appointed Amar Sethi, M.D., Ph.D. as its Chief Scientific Officer. At VivoSim, Dr. Sethi will lead scientific strategy across toxicology, translational models, bio...
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms Distinguished drug-development and biomark...